Covagen has expanded its senior management team with the appointment of Elias Papatheodorou as Chief Business Officer. He brings 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements.
Prior to joining Covagen, Papatheodorou was Senior Vice President, Business Development and Operations at Medigene. Before this, he was Chief Executive of Novosom where he completed a series of collaborative agreements with pharmaceutical companies in Europe, US and Asia.
Papatheodorou was also Vice President of Business Development and Marketing for the medical imaging company ATI and held positions of increasing responsibility at Coca-Cola and Philip Morris.
Covagen, based in Zurich-Schlieren in Switzerland, develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer.
